Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAIL-004: Baricitinib, Remdesivir, and Tocilizumab for Hospitalized COVID-19
NCT04321993Phase 2Unknown
- Start
- Apr 2020
- Primary completion
- Apr 2024
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of baricitinib, remdesivir and tocilizumab in coronavirus disease 2019 (COVID-19). Status: unknown.
02
Drugs
baricitinibremdesivirtocilizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04321993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04321993.